Combined chemoradiation in high-risk endometrial cancer: benefit or not?

Recently, the final results of the large scaled randomized intergroup trial named PORTEC-3 was released showing that adjuvant chemotherapy given concurrently during and after pelvic irradiation in women with high-risk endometrial carcinoma provided no significant 5-year failure-free (FFS) or overall survival (OS) benefit, compared with radiotherapy (RT) alone (1).